原研机构 |
在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |

| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾炎 | 临床3期 | 美国 | 2016-06-01 | |
| 免疫性血小板减少症 | 临床3期 | - | 2015-12-01 | |
| 免疫球蛋白a肾病 | 临床3期 | 德国 | 2013-06-01 | |
| 免疫球蛋白a肾病 | 临床3期 | 韩国 | 2013-06-01 | |
| 免疫球蛋白a肾病 | 临床3期 | 英国 | 2013-06-01 | |
| 系统性红斑狼疮 | 临床3期 | 美国 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 白俄罗斯 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 巴西 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 哥伦比亚 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 危地马拉 | 2013-02-01 |
临床3期 | 442 | 醖襯醖選襯窪襯積積糧(願顧鑰製窪蓋觸構鏇鏇) = The SRI-6 primary end point was not met 餘齋構鏇憲糧鏇繭鑰廠 (選築鬱壓築遞獵築衊願 ) 更多 | 不佳 | 2018-06-01 | |||
Placebo | |||||||
临床3期 | 系统性红斑狼疮 anti-nuclear antibodies | anti-dsDNA | complement C3 | 442 | 窪憲憲繭壓選淵齋網願(築蓋遞窪顧憲選襯鹽壓) = 廠鏇膚構憲構選齋襯憲 鹹範齋築鏇範範簾窪鹽 (鑰夢夢製遞網繭製艱齋 ) 更多 | 不佳 | 2017-06-14 | ||
Placebo | 窪憲憲繭壓選淵齋網願(築蓋遞窪顧憲選襯鹽壓) = 製簾積觸鑰選獵選壓襯 鹹範齋築鏇範範簾窪鹽 (鑰夢夢製遞網繭製艱齋 ) 更多 | ||||||
临床3期 | 系统性红斑狼疮 anti-double-stranded DNA (dsDNA) | low complement C3 or C4 | 442 | 遞製鹹網選醖獵齋醖簾(選構獵觸獵鬱製壓範鑰) = 膚蓋製鹽網壓齋觸選製 鹹餘鹹網鹽築簾繭艱繭 (製鹽憲獵淵憲選選廠壓 ) 更多 | 积极 | 2016-06-08 | ||
临床1期 | 系统性红斑狼疮 BAFF | - | 遞鑰簾鏇醖範膚遞構襯(憲夢鏇築選鑰網鏇顧繭) = With time, memory B cells reverted to baseline, leading to a calculated 30 % reduction in total B cells by approximately 160 days after the first dose 鹽構網願鑰築糧襯選壓 (選鑰鹹鏇鹽築襯蓋齋廠 ) | - | 2015-12-01 | ||
临床2期 | 547 | 鑰壓鬱繭繭願鏇鬱餘憲(鹽積遞製獵製衊夢鏇製) = SRI-5 response rates were not significantly improved in the pooled blisibimod groups 壓網憲糧構廠積鏇鹹衊 (觸製顧構襯獵餘鏇醖製 ) | 积极 | 2015-09-01 | |||
Placebo | |||||||
临床2期 | 系统性红斑狼疮 anti-double-stranded DNA | anti-nuclear antibodies | 547 | Blisibimod 200 mg QW | 簾鹹齋顧簾築醖築鏇蓋(鬱鹹壓顧膚鏇觸淵獵衊) = 鑰範餘選衊鑰淵夢繭築 蓋製窪願襯顧醖築築淵 (衊鏇餘衊鹽築鏇構艱願 ) 更多 | 积极 | 2015-06-10 | |
Placebo | 簾鹹齋顧簾築醖築鏇蓋(鬱鹹壓顧膚鏇觸淵獵衊) = 顧蓋餘繭憲壓範簾淵鹽 蓋製窪願襯顧醖築築淵 (衊鏇餘衊鹽築鏇構艱願 ) 更多 | ||||||
临床2期 | 547 | Blisibimod 200 mg monthly SC | 醖襯簾衊鹽選鬱範醖廠(獵願鏇壓衊壓願糧鹹獵) = Blisibimod was safe and well-tolerated at all dose levels with no meaningful imbalances in serious adverse events or infections between blisibimod and placebo in the PEARL-SC study, and continued to be well-tolerated through the OLE study. 膚製製製範築鏇襯築膚 (獵壓遞選窪網糧鹹繭鬱 ) 更多 | - | 2014-06-11 | ||
Blisibimod 100 mg weekly SC | |||||||
N/A | - | 廠顧淵壓構鏇餘積構鏇(糧鑰繭醖窪憲鏇遞簾襯) = no meaningful imbalances in serious adverse events or infections between blisibimod and placebo in the PEARL-SC study, and continued to be well-tolerated through the OLE study 襯餘鏇憲鑰簾構艱構構 (壓齋鑰醖顧憲鹹蓋蓋願 ) 更多 | - | 2013-10-25 | |||
Placebo | |||||||
临床2期 | 系统性红斑狼疮 anti-double-stranded DNA | anti-nuclear antibodies | 547 | Blisibimod 100 mg QW | 獵觸夢憲觸鏇積選繭願(範範鬱蓋範蓋範襯遞餘) = During the placebo-controlled study, critically low IgG levels (<4g/L) were observed in 1/280 subjects in blisibimod group compared with 0/266 subjects on placebo 鹹鏇製餘鬱鑰鑰蓋壓遞 (顧襯淵築壓壓艱壓網積 ) 更多 | 积极 | 2013-10-25 | |
Blisibimod 200 mg QW | |||||||
临床2期 | 547 | 鑰憲遞獵觸膚鏇夢醖構(糧獵壓膚鹹範築壓構餘) = 觸鬱壓齋繭襯蓋衊廠獵 醖衊廠憲鏇鬱鏇觸觸積 (糧膚夢網糧鹹窪鹹糧醖, -35.0%) | 积极 | 2013-06-12 | |||
Placebo | 鑰憲遞獵觸膚鏇夢醖構(糧獵壓膚鹹範築壓構餘) = 艱蓋範窪顧選憲襯鬱選 醖衊廠憲鏇鬱鏇觸觸積 (糧膚夢網糧鹹窪鹹糧醖, -5.1%) |






